NCT00876642

Brief Summary

Radiation therapy (RT) has been a component of breast cancer treatment for almost 100 years. Although initially used for the treatment of chest wall recurrences after mastectomy and for advanced inoperable disease, RT has evolved into a critical component of early therapy for women with an intact breast following lumpectomy and for mastectomized women who are at high risk for local failure. Currently breast cancer patients need a multidisciplinary management including surgery, chemotherapy and radiotherapy, radiotherapy has a significant role in loco regional control of the disease. It is estimated that 87% of these women will develop some degree of radiation-induced dermatitis, varying from mild to brisk erythema or even moist desquamation. Topical agents, such as corticosteroid creams and other products including Aquaphor (Beirsdorf Inc, Wilton, CT), and trolamine (Biafine; Genmedix Ltd, France), are commonly prescribed at the onset of radiation dermatitis or, in some institutions, at the beginning of radiotherapy. The aim of this randomized phase III study was to assess the effectiveness of aloe vera cream for the prevention of acute radiation-induced dermatitis of grade 2 or higher during postoperative radiotherapy for breast cancer, compared to best supportive care. The secondary objectives were to assess pain, treatment interruption as a result of skin reactions, and the quantity of life during the treatment.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
137

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Mar 2007

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2007

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2008

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2008

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

April 5, 2009

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 7, 2009

Completed
Last Updated

April 7, 2009

Status Verified

April 1, 2009

Enrollment Period

1.5 years

First QC Date

April 5, 2009

Last Update Submit

April 6, 2009

Conditions

Keywords

Radiation dermatitisbest supportive careAloe vera gelphase III study was to assess the effectiveness of aloe vera and vitamin E.

Outcome Measures

Primary Outcomes (1)

  • Acute radiation-induced dermatitis of grade 2 or higher during postoperative radiotherapy for breast cancer.

Secondary Outcomes (1)

  • quality of life,interruptions of treatment and pain.

Study Arms (2)

1

EXPERIMENTAL
Drug: Aloe vera gel

2

NO INTERVENTION

Interventions

The aloe vera gel which was commercially available, contained water, aloe vera, D-panthenol, triethanolamine, carbomer 934P, hyaluronic acid, potassium sorbate, diazolidinyl urea, methylparaben, and propylparaben.

1

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • The women had to be 18 to 75 years of age with a nonmetastatic breast adenocarcinoma treated by either lumpectomy or mastectomy with or without adjuvant postoperative chemotherapy or hormonal treatment, and referred to the Department of Radiotherapy for postoperative radiotherapy. Concomitant chemotherapy was allowed.

You may not qualify if:

  • Women with bilateral cancer, patients who were allergic to either of the two agents, and pregnant women were excluded.
  • No rash, ulceration, bleeding, or unhealed scar was allowed in the treatment area.
  • Patients were excluded for: prior radiation therapy (RT), mastectomy, skin involvement by tumor, history of, or current connective tissue disorder, medical contraindication (allergy or sensitivity) to Aloevera or planned BSC, and inability to comply with treatment regime. The use of bolus was prohibited.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Gustavo Viani

Marília, Sao Paulo\brazil, 17501570, Brazil

Location

MeSH Terms

Conditions

Radiodermatitis

Interventions

Aloe vera gel

Condition Hierarchy (Ancestors)

DermatitisSkin DiseasesSkin and Connective Tissue DiseasesRadiation InjuriesWounds and Injuries

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

April 5, 2009

First Posted

April 7, 2009

Study Start

March 1, 2007

Primary Completion

September 1, 2008

Study Completion

December 1, 2008

Last Updated

April 7, 2009

Record last verified: 2009-04

Locations